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Introduction
Secondary central nervous system lymphoma (SCNSL) 
is a lymphoma not derived from central nervous system 
(CNS) and can be a recurrence in the CNS or a part of 
a progressive disease.1 It is typically a non-Hodgkin 
lymphoma. SCNSL divided into subtype, leptomeningeal 
and parenchymal, or as a combination of this two type. 
Leptomeningeal lymphoma accounts for two-thirds 
of cases of secondary CNS lymphomas, the one-third 
remaining is parenchymal disease.2 because of the lack of 
clinical data about isolated SCNSL, a standard treatment 
regimen, and overall prognosis have not identified.3
  
Case Presentation
A 61-year-old woman with confusional state and amnesia 
admitted in our hospital. The patient had muscle 
weakness, right side paresis and was ill but not toxic. 
She had a medical history of breast lymphoma type 
diffused large B-cell lymphoma (DLBCL) 18 months ago, 
which treated with chemotherapy and radiotherapy. The 
patient family history was unremarkable. HIV test was 
negative. A metastasis workup revealed no other site of 
involvement. She had three recurrences despite treatment 
which means the aggressive type of disease. On brain 
magnetic resonance imaging (MRI) she had a mass lesion 
(43.34.38 mm) on left frontal and periventricular region 
with peripheral edema, enhanced on T1+GAD sequence 
and restricted on diffusion weighted imaging (DWI), 
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Abstract
Secondary central nervous system lymphoma (SCNSL) is known as a rare disease. The risk 
factor of developing SCNSL is primary lymphoma type and site of involvement. We present 
a patient with an altered mental status known case of breast diffused large B-cell lymphoma 
(DLBCL) who underwent stereotactic biopsy because of a left periventricular mass lesion, 
which diagnosed as secondary brain lymphoma after pathologic typing. Because of limited 
data about the secondary central nervous system, lymphoma and it is a risk factor, we reported 
an aggressive breast DLBCL with brain involvement.
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compatible with high-grade glioma and lymphoma.
The patient underwent a stereotactic biopsy. The result 
of biopsy was malignant high-grade B-CELL lymphoma 
after CD marker typing, diagnosed as SCNSL.
The patient received a high dose of methotrexate 
chemotherapy and planed for whole brain radiotherapy.
Discussion 
The incidence of SCNSL depends on the type of primary 
lymphoma, the involvement of more than one site, stage 
of the primary disease and grade of the International 
Prognostic Index.1,2 patient with involvement of the 
breast, testis, and bone marrow as the primary disease is at 
a higher risk of developing SCNSL.4 The immunodeficient 
population are at the highest risk. Because of better 
diagnostic and treatment approach of primary and 
secondary CNS lymphoma, focusing more study on 
Figure 1. T1+GAD MRI imaging show enhancement and 
restricted on DWI.
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treatment of the elderly patient is needed.5
As noted the histologic grade of the primary lymphoma 
relate to developing of SCNSL. Up on the primary 
lymphoma classification, indolent, aggressive, or highly 
aggressive, there is a 3%, 9%, and 27% risk of developing 
SCNSL. Especially for diffuse large B-cell lymphoma 
(DLBCL), the incidence has reported  5%, but when the 
primary lymphoma is the mediastinal large B-cell type, 
the risk of SCNSL raise to 19%. Indolent lymphomas have 
a low risk of recurrence, but when CNS involvement has 
proved, it is usually after the histologic transformation to 
a more aggressive type.3,6
Treatment method and CNS prophylaxis regime after 
the diagnose of primary lymphoma is a field of excellent 
research. Large retrospective trial studies found that an 
intravenous (IV) rituximab added to cyclophosphamide, 
doxorubicin, vincristine, and prednisolone (CHOP) 
therapy has decreased the incidence of SCNSL from 6.9% 
to 4.1%.7
The use of IV MTX has increased survival times for 
isolated SCNSL, especially for parenchymal SCNSL.7
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